GlassScriptPhysician profile
Jurgen H Straub
NPI 1063679108
$12,485.43
in general payments reported to CMS, 2019-2025
29 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,274 · 2020: $927 · 2021: $1,485 · 2022: $1,875 · 2023: $2,238 · 2024: $1,690 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,924.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,213.65 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,904.42 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $1,416.95 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,154.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $993.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $732.52 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.93 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $517.36 | 2022-2023 | |
| Esperion Therapeutics, INC. | $502.77 | 2020-2021 | |
| Pfizer INC. | $384.76 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $300.91 | 2024-2025 | Voquezna |
| Abbvie INC. | $256.21 | 2019-2024 | Vraylar, Qulipta, Ubrelvy |
| Abbott Laboratories | $226.26 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $202.24 | 2019-2025 | Austedo Xr |
| Exact Sciences Corporation | $179.15 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $131.45 | 2019-2025 | |
| Astellas Pharma US INC | $121.50 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $81.62 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.60 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.33 | 2022 | |
| Verona Pharma, INC. | $61.29 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.60 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $56.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.01 | 2019-2021 | |
| Kyowa Kirin, INC. | $44.06 | 2023 | Crysvita |
| Dexcom, INC. | $37.85 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $17.70 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $16.35 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jurgen Straub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.